FoRx Therapeutics AG
|Category:||Emerging Biotech Company|
|Date:||April 24, 2023|
|Speaker:||Tarig Bashir, CEO|
FoRx Therapeutics focuses on the discovery and development of small molecule inhibitors against key proteins involved in the response to oncogene-induced DNA replication stress, which constitutes an innovative approach to identifying novel, targeted anti-cancer drugs. The company has currently 15 employees and is backed by a syndicate of investors that include EQT Life Sciences, Novartis Venture Fund, Pfizer Ventures, Omega Funds and M Ventures.